All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena

March 9th 2024

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

FDA's MIDAC Votes in Support of Benefit-Risk Profile of Lumisight Optical Imaging Agent for Breast Cancer Detection

March 9th 2024

The FDA's Medical Imaging Drugs Advisory Committee voted 16 to 2 in support of the benefit-risk profile of Lumisight.

Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer

March 9th 2024

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

Dr Tagawa on the Role of PARP Inhibitors in Prostate Cancer Treatment

March 9th 2024

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.

Dr Dreicer on Improving Clinical Trial Design in Prostate Cancer

March 9th 2024

Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.

Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation

March 8th 2024

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.

PRMT5 Inhibitors Plus Antiestrogens May Combat Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer

March 8th 2024

PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.

ADCs Serve as “Exciting and Effective Drug Delivery System” in HR+/HER2– Breast Cancer

March 8th 2024

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.

Racial Disparities Magnified in Cardiac Dose, Toxicity Differences With RT for Breast Cancer

March 8th 2024

Racial and ethnic disparities for mortality are present in breast cancer, especially as it relates to radiation therapy toxicity and cardiac dose.

Empowering Women in Oncology and Beyond on International Women’s Day

March 8th 2024

Eirwen M. Miller, MD, discusses her experience in the oncology field and the importance of ensuring gender is not a defining quality for oncologists.

Expanding the Patient Pool for Immunotherapies

March 8th 2024

Although immune checkpoint inhibitors can yield dramatic results and give some patients many years of life, some patients do not yield benefit.

FDA Awards Orphan Drug Designation to Cambritaxestat for Pancreatic Cancer

March 8th 2024

Cambritaxestat has received orphan drug designation from the FDA for the treatment of patients with pancreatic cancer.

T-DXd Has Intracranial Activity in Meta-Analysis of HER2+ Breast Cancer Brain Metastases

March 8th 2024

Trastuzumab deruxtecan has significant intracranial activity in patients with HER2-positive breast cancer brain metastases, regardless of subgroup.

UV1 Vaccination Plus Nivolumab/Ipilimumab Falls Short in Metastatic Melanoma

March 7th 2024

The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma.

FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma

March 7th 2024

The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for select patients with relapsed/refractory follicular lymphoma.

ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors

March 7th 2024

ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.

Eftilagimod Alpha Plus Chemotherapy Lead-In Proves Safe in HR+/HER2-Low Breast Cancer

March 7th 2024

Eftilagimod alpha in combination with chemotherapy displayed a manageable safety profile in HR+/HER2-low breast cancer.

FDA Approves Frontline Nivolumab Plus Chemo for Unresectable or Metastatic Urothelial Carcinoma

March 7th 2024

The FDA has approved nivolumab plus cisplatin and gemcitabine for first-line use in adult patients with unresectable or metastatic urothelial carcinoma.

Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should Be Lower

March 7th 2024

Survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.

DREAMM-8 Produces Positive Topline Results in Relapsed/Refractory Multiple Myeloma

March 7th 2024

Belantamab mafodotin plus pomalidomide and dexamethasone extended PFS in relapsed/refractory multiple myeloma.